Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 11/20 | 0.52 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.33 |
| ▸ | OTC | P00480 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11327768 | 0.78 | FDPS (0.70) | FDPSSMPD1LMNAPDE3AADRB3 | |
| SCHEMBL11326626 | 0.78 | FDPS (0.55) | FDPSSMPD1LMNAPDE3AADRB3 | |
| SCHEMBL1285892 | 0.77 | FDPS (0.61) | FDPSSMPD1LMNAPDE3AADRB3 | |
| SCHEMBL4098390 | 0.73 | FDPS (0.56) | FDPSSMPD1LMNAPDE3AADRB3 | |
| SCHEMBL457919 | 0.73 | FDPS (0.64) | FDPSSMPD1LMNAPDE3AADRB3 | |
| SCHEMBL8825784 | 0.73 | FDPS (0.77) | FDPSSMPD1LMNAPDE3AADRB3 | |
| SCHEMBL5162874 | 0.73 | FDPS (0.64) | FDPSSMPD1LMNAPDE3AADRB3 | |
| SCHEMBL4104675 | 0.73 | FDPS (0.73) | FDPSSMPD1LMNAPDE3AADRB3 | |
| SCHEMBL1285910 | 0.73 | FDPS (0.64) | FDPSSMPD1LMNAPDE3AADRB3 | |
| Tromethamine SCHEMBL1509014 | 0.71 | LMNA (0.67) | FDPSSMPD1LMNAPDE3AADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117969859-B | Metabolic biomarker for polycystic ovary syndrome and application thereof | 山东大学 | 2024-09-06 | — | — | CN | claimed |
| US-3940436-A | Substituted ethane diphosphonic acids and salts and esters thereof | MONSANTO COMPANY (US) | 1976-02-24 | — | — | US | claimed |
| US-20260076944-A1 | COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH | UNIV CALIFORNIA (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260022384-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2026-01-22 | — | — | US | disclosed |
| US-12491217-B2 | Compositions and methods for promoting healthy neural development in an unborn baby | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-09 | — | — | US | disclosed |
| US-20230348785-A1 | FLAME RETARDANT FOR WOODY MATERIALS AND FLAME-RETARDANT WOODY MATERIAL | DAIHACHI CHEM IND (JP) | 2023-11-02 | — | — | US | disclosed |
| US-11760936-B2 | Flame retardant for woody materials and flame-retardant woody material | DAIHACHI CHEMICAL INDUSTRY CO., LTD. (JP) | 2023-09-19 | — | — | US | disclosed |
| US-20230181621-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2023-06-15 | — | — | US | disclosed |
| US-20230172955-A1 | ETHANOLAMINE-BASED LIPID BIOSYNTHETIC COMPOUNDS, METHOD OF MAKING AND USE THEREOF | METANOI THERAPEUTICS INC (US) | 2023-06-08 | — | — | US | disclosed |
| EP-2618832-B1 | COMPOSITION COMPRISING SOD, LUTEIN AND ZEAXANTHIN | OMNIVISION GMBH (DE) | 2023-06-07 | — | — | EP | disclosed |
| US-20230144385-A1 | ETHANOLAMINE FORMULATION FOR TREATING EPITHELIAL OVARIAN CARCINOMA | METANOI THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| WO-2005082144-A1 | METHYLATION INHIBITOR COMPOUNDS | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER (US) | 2005-09-09 | — | — | WO | disclosed |
| EP-1503800-A1 | TREATMENT AND PREVENTION OF TISSUE DAMAGE | Pentraxin Therapeutics Limited (GB) | 2005-02-09 | — | — | EP | disclosed |
| WO-2003097104-A1 | TREATMENT AND PREVENTION OF TISSUE DAMAGE | PENTRAXIN THERAPEUTICS LIMITED (GB) | 2003-11-27 | — | — | WO | disclosed |
| US-4615977-A | AMINE DERIVATIVES PROMOTE GROWTH WITH LOW SERUM CONCENTRATIONS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1986-10-07 | — | — | US | disclosed |
| EP-0082974-B1 | METHOD FOR THE CULTIVATION OF NORMAL DIPLOID CELLS AND CULTIVATION MEDIUM USED THEREFOR | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1986-05-14 | — | — | EP | disclosed |
| US-3962318-A | Substituted ethane diphosphonic acids and salts and esters thereof | MONSANTO COMPANY (US) | 1976-06-08 | — | — | US | disclosed |
| US-3957858-A | SUBSTITUTED ETHANE DIPHOSPHONIC ACIDS AND SALTS AND ESTERS THEREOF | MONSANTO COMPANY (US) | 1976-05-18 | — | — | US | disclosed |
| US-3944599-A | Substituted ethane diphosphonic acids and salts | MONSANTO COMPANY (US) | 1976-03-16 | — | — | US | disclosed |
| US-3940436-A | Substituted ethane diphosphonic acids and salts and esters thereof | MONSANTO COMPANY (US) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144385-A1 | ETHANOLAMINE FORMULATION FOR TREATING EPITHELIAL OVARIAN CARCINOMA | PHOSPHO1, EGLN3, HIF1AN | FDPS 4598/4885SMPD1 374/4885LMNA 1752/4885 |
| US-20230181621-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | ASNS, GLS, GLS2 | FDPS 27/4885SMPD1 1738/4885LMNA 3822/4885 |
| US-20260076944-A1 | COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH | IDO1, INMT, IDO2 | FDPS 3139/4885SMPD1 4363/4885LMNA 4468/4885 |
| US-20230172955-A1 | ETHANOLAMINE-BASED LIPID BIOSYNTHETIC COMPOUNDS, METHOD OF MAKING AND USE THEREOF | PHOSPHO1, SGMS2, CHKB | FDPS 195/4885SMPD1 62/4885LMNA 3483/4885 |
| US-20260022384-A1 | ASPARAGINE SYNTHETASE INHIBITORS AND USES THEREOF | ASNS, AARS1, NARS1 | FDPS 284/4885SMPD1 3954/4885LMNA 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.